Source comparison
Melanotan-1 vs PT-141: Research Application Comparison
Primary Receptor Target MC1R (melanocyte pigmentation) MC4R (hypothalamic sexual arousal pathways) Completely different mechanisms. Not interchangeable FDA-Approved Indication Erythropoietic protoporphyria (EPP) Hypoactive sexual desire disorder (HSDD) in prem
This comparison does not assign a generated winner or score.
- Primary Receptor Target
- MC1R (melanocyte pigmentation)
- MC4R (hypothalamic sexual arousal pathways)
- Completely different mechanisms. Not interchangeable
- FDA-Approved Indication
- Erythropoietic protoporphyria (EPP)
- Hypoactive sexual desire disorder (HSDD) in premenopausal women
- Both are orphan/specialty drugs with narrow approved uses
- Route of Administration
- 60-day subcutaneous implant (Scenesse) or daily SC injection (research)
- Subcutaneous injection as needed, 45 min before activity
- Implant eliminates daily dosing; PT-141 requires activity timing
- Onset of Visible Effect
- Melanogenesis begins within 48–72 hours; full tanning takes 2–3 weeks
- Sexual arousal effects within 45–90 minutes of administration
- Melanotan-1 is cumulative; PT-141 is acute and reversible
- Most Common Side Effect
- Nausea (30%), injection site reactions, darkening of nevi
- Nausea (40–50%), flushing (20–30%), transient hypertension
- PT-141 has higher nausea incidence due to MC4R in area postrema
- Cardiovascular Restrictions
- None. Safe in hypertensive patients
- Contraindicated in uncontrolled hypertension or CVD
- PT-141's BP elevation is small but clinically relevant at scale
- Photosensitivity Impact
- Increases eumelanin production → photoprotection
- No direct pigmentation effect at therapeutic doses
- Only melanotan-1 provides UV defence. Core mechanism difference
- Research Availability
- Available as lyophilised powder for reconstitution at Real Peptides
- Both require cold-chain storage and precise reconstitution protocols